Warning letter
Lilly del Caribe, Inc. (PR05) [ARCHIVED]: warning letter of Feb 5, 2010
FDA warning letter 79564 · San Juan District Office
Key facts
| Reference number | 79564 |
|---|---|
| Company | Lilly del Caribe, Inc. (PR05) [ARCHIVED] |
| Subject | CGMP/Active Pharmaceutical Ingredients/Adulterated |
| Issue date | Feb 5, 2010 |
| Posted date | Feb 5, 2010 |
| Issuing office | San Juan District Office |
| Product type | Drugs |
| Inspection city | Carolina |
| Inspection ZIP | 00985 |
| Inspection start date | Jul 8, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: